Exscientia plc. (6/6/23). "Press Release: Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference". Oxford.

	Organisation	Exscientia plc (Nasdaq: EXAI)
	Group	Recursion Pharmaceuticals (Group)
	Organisation 2	Goldman Sachs (Group)
	Product	Goldman Sachs Annual Global Healthcare Conference 2023 Dana Point
	Product 2	AI-based drug discovery / AI-based drug development
	Index term	Exscientia–Goldman Sachs: investor conference, 202306 supply service Exscientia presents at Goldman Sachs Annual Global Healthcare Conference 2023
	Person	Sherman, Sara (Exscientia 202109 Investor Relations)
	Person 2	Stohlmann, Oliver (Exscientia 202306 Media Relations)

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST).

A live webcast of the fireside chat will be available on the Company’s website, under the “Investors & Media” section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Investor Relations:
Sara Sherman
investors@exscientia.ai

Media:
Oliver Stohlmann
media@exscientia.ai

Record changed: 2024-01-06